کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5120885 1486262 2017 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan
ترجمه فارسی عنوان
علل مرگ و سالهای انتظار زندگی در میان افراد وابسته به مواد افیونی در ایالات متحده و تایوان از بین رفته است
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی روانپزشکی و بهداشت روانی
چکیده انگلیسی

AimsThis study compared the cause-specific standardized mortality ratios (SMRs) and expected years of life lost (EYLL) among opioid-dependent individuals in the United States and Taiwan.MethodsSurvival data came from two cohorts followed until 2014: The U.S. data were based on a randomized trial of 1267 opioid-dependent participants enrolled between 2006 and 2009; the Taiwan data were from a study of 983 individuals that began in 2006, when opioid agonist treatment (OAT) was implemented in Taiwan. SMRs were calculated for each national cohort and compared. Kaplan–Meier estimation was performed on the survival data, then lifespans were extrapolated to 70 years (840 months) to estimate life expectancy using a semi-parametric method. EYLLs for both cohorts were estimated by subtracting their life expectancies from the age- and gender-matched referents within the general population of their respective country.ResultsCompared with age- and gender-matched referents, the SMRs were 3.2 for the U.S. sample and 7.8 for the Taiwan sample; the EYLLs were 7.7 and 16.4 years, respectively. Half of decedents died of unnatural causes in both cohorts; overdose deaths predominated in the U.S. and suicide in Taiwan.ConclusionsOur study identified differences by country in EYLL and causes of deaths. These findings suggest that intervention strategies to reduce mortality risk by overdose (particularly in the U.S.) and suicide (particularly in Taiwan) are urgently needed in these countries.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Drug Policy - Volume 43, May 2017, Pages 1–6